Home » Newsletters » BioWorld Science

BioWorld Science

March 22, 2006

View Archived Issues

Research Foundations of Orion and Farmos plan to merge

Laureate Pharma and Bradmer sign development and manufacturing agreement

p53 gene therapy feasible, active in esophageal carcinoma patients

Futility trial indicates creatine and minocycline deserve phase III investigation

Antihypertensives linked to reduced incidence of Alzheimer's disease

Antitumor and antiangiogenic validation of anti-S1P MAb from Lpath

Lilly and Biosite collaborate on biomarkers for Xigris therapy

Orphan drug designation for Zadaxin in malignant melanoma

Schering-Plough and PTC Therapeutics establish HCV collaboration

New phase II study for SNS-595 in small cell lung cancer

Medidur phase III trial recommended to continue

Preliminary 48-week from phase III psoriasis trial of ISA-247

Exelixis and Sankyo to develop novel therapies for cardiovascular disease

Phase II trial studying VRX-496 for HIV

NanoViricides achieves positive results in initial FluCide-I studies

POET-1 study of Altropane ended early for evaluation of data

NicOx and Merck to develop new antihypertensive drugs

Phase I/II study of obesity drug TM-30338 meets endpoints

Atorvastatin/glatiramer combination synergistic in multiple sclerosis model

LY-450139 investigated in Alzheimer's disease

RON: A novel target for anticancer therapy

OSI-930 reported safe in healthy volunteers

Thiovir active against H5N1 avian influenza chimeric virus strains

Elan completes sale of European Prialt rights to Eisai

Three new studies evaluate GEM OS1 in orthopedic indications

STRIDE study of I-vation Intravitreal Implant completes enrollment

Recent patents cover novel compounds for Alzheimer's and other neurological disorders

Therapeutic agents for gastrointestinal disorders disclosed in recent patent literature

Novel HIV vaccines jointly reported by Progenics and the Sloan-Kettering Institute

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...